{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:43:17Z","timestamp":1789735397967,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.beha.2023.101522","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:29:11Z","timestamp":1698784151000},"page":"101522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The international cooperative Gaucher group (ICCG) Gaucher registry"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9100-4733","authenticated-orcid":false,"given":"Neal J.","family":"Weinreb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.beha.2023.101522_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","volume":"132","author":"Weinreb","year":"2021","journal-title":"Mol Genet Metabol"},{"issue":"2","key":"10.1016\/j.beha.2023.101522_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bcmd.2016.10.002","article-title":"Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy","volume":"68","author":"Weinreb","year":"2018","journal-title":"Blood Cells Mol Dis"},{"issue":"21","key":"10.1016\/j.beha.2023.101522_bib3","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2023.101522_bib4","first-page":"S2","article-title":"The history and accomplishments of the ICGG Gaucher registry","volume":"90","author":"Weinreb","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2023.101522_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13023-022-02517-0","article-title":"Rare lysosomal disease registries: lessons learned over three decades of real-world evidence","volume":"17","author":"Mistry","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beha.2023.101522_bib6","unstructured":"\u201cRegistry.\u201d Merriam-Webster.com Dictionary, Merriam-Webster, https:\/\/www.merriam-webster.com\/dictionary\/registry. Accessed 14 September. 2023.."},{"key":"10.1016\/j.beha.2023.101522_bib7","unstructured":"McIntosh MA. An Historical Overview of the Census in the Ancient and Medieval World. https:\/\/brewminate.com\/an-historical-overview-of-the-census-in-the-ancient-and-medieval-world\/. Accessed September\/14\/2023.."},{"key":"10.1016\/j.beha.2023.101522_bib8","unstructured":"Hebrew Bible. Exodus; 30:11-16."},{"key":"10.1016\/j.beha.2023.101522_bib9","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1056\/NEJMp2306872","article-title":"The accelerated approval program for cancer drugs \u2014 finding the right balance","volume":"389","author":"Gyawali","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.beha.2023.101522_bib10","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beha.2023.101522_bib12","first-page":"177","article-title":"The pathology of Gaucher disease","volume":"95","author":"Lee","year":"1982","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.beha.2023.101522_bib13","series-title":"Warren grant magnuson clinical center","year":"1995"},{"key":"10.1016\/j.beha.2023.101522_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1615\/CritRevOncog.2013005921","article-title":"Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy","volume":"18","author":"Weinreb","year":"2013","journal-title":"Crit Rev Oncog"},{"issue":"2","key":"10.1016\/j.beha.2023.101522_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.24957","article-title":"GOS Study group. Demographics and patient characteristics of 1209 patients with Gaucher disease: descriptive analysis from the Gaucher Outcome Survey (GOS)","volume":"93","author":"Zimran","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2023.101522_bib16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bcmd.2016.10.003","article-title":"Reported outcomes of 453 pregnancies in patients with Gaucher disease: an analysis from the Gaucher outcome survey","volume":"68","author":"Lau","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beha.2023.101522_bib17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bcmd.2016.10.014","article-title":"Treatment patterns from 647 patients with gaucher disease: an analysis from the gaucher outcome survey","volume":"68","author":"Deegan","year":"2018","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"10.1016\/j.beha.2023.101522_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-022-02289-7","article-title":"Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS)","volume":"17","author":"Titievsky","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beha.2023.101522_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","article-title":"The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients","volume":"7","author":"Stirnemann","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.beha.2023.101522_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-020-01520-7","article-title":"Identification of risk features for complication in Gaucher's disease patients: a machine learning analysis of the Spanish registry of Gaucher disease","volume":"15","author":"Andrade-Campos","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.beha.2023.101522_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13023-023-02828-w","article-title":"A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative","volume":"18","author":"Collin-Histed","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.beha.2023.101522_bib22","first-page":"129","article-title":"Pain assessment: global use of the brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"issue":"1","key":"10.1016\/j.beha.2023.101522_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13023-021-02163-y","article-title":"Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials","volume":"17","author":"Elstein","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.beha.2023.101522_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents, and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"10.1016\/j.beha.2023.101522_bib25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0049-0172(96)80001-1","article-title":"Clinical utility of bone mass measurements in adults: consensus of an international panel","volume":"25","author":"Miller","year":"1996","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.beha.2023.101522_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s002560050313","article-title":"Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement","volume":"26","author":"Hermann","year":"1997","journal-title":"Skeletal Radiol"},{"issue":"6","key":"10.1016\/j.beha.2023.101522_bib27","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: from pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.beha.2023.101522_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgme.2020.07.011","article-title":"Unraveling the mystery of Gaucher bone density pathophysiology","volume":"132","author":"Rozenfeld","year":"2021","journal-title":"Mol Genet Metabol"},{"issue":"1","key":"10.1016\/j.beha.2023.101522_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GIM.0b013e3181c39194","article-title":"A validated disease severity scoring system for adults with type 1 Gaucher disease","volume":"12","author":"Weinreb","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.beha.2023.101522_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","article-title":"Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)","volume":"10","author":"Weinreb","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.beha.2023.101522_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2012.04.002","article-title":"Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment","volume":"49","author":"Mekinian","year":"2012","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beha.2023.101522_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcmd.2016.11.005","article-title":"The role of high-density lipoprotein in Type 1 Gaucher disease","volume":"68","author":"Watad","year":"2018","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"10.1016\/j.beha.2023.101522_bib33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MBC.0b013e3283424809","article-title":"D-dimer assay in Egyptian patients with Gaucher disease: correlation with bone and lung involvement","volume":"22","author":"Sherif","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.beha.2023.101522_bib34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cbpa.2019.10.006","article-title":"Glycosphingolipids and lysosomal storage disorders as illustrated by Gaucher disease","volume":"53","author":"Aerts","year":"2019","journal-title":"Curr Opin Chem Biol"},{"issue":"1\u20132","key":"10.1016\/j.beha.2023.101522_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0009-8981(01)00798-7","article-title":"Gaucher and Niemann-Pick diseases--enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards","volume":"317","author":"Chamoles","year":"2002","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.beha.2023.101522_bib36","article-title":"A new multiplex analysis of glucosylsphingosine and globotriaosylsphingosine in dried blood spots by tandem mass spectrometry","volume":"37","author":"Van Baelen","year":"2023","journal-title":"Mol Genet Metab Rep"},{"issue":"9","key":"10.1016\/j.beha.2023.101522_bib37","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00702-022-02531-3","article-title":"Glucocerebrosidase mutations and Parkinson disease","volume":"129","author":"Vieira","year":"2022","journal-title":"J Neural Transm"},{"key":"10.1016\/j.beha.2023.101522_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114402","article-title":"Lysosomal functions and dysfunctions: molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease","volume":"187","author":"Horowitz","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"10.1016\/j.beha.2023.101522_bib39","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ajh.26675","article-title":"Cancer risk and gammopathies in 2123 adults with gaucher disease type 1 in the international gaucher group gaucher registry","volume":"97","author":"Rosenbloom","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2023.101522_bib40","unstructured":"Alglucerase injection (Ceredase\u00ae) \u2013 Gaucher disease. https:\/\/www.ninds.nih.gov\/about-ninds\/impact\/ninds-contributions-approved-therapies\/alglucerase-injection-ceredaser-gaucher-disease, Accessed 26 September 2023."},{"issue":"5","key":"10.1016\/j.beha.2023.101522_bib41","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198509000-00003","article-title":"Skeletal complications of Gaucher disease","volume":"64","author":"Stowens","year":"1985","journal-title":"Medicine (Baltim)"},{"issue":"16","key":"10.1016\/j.beha.2023.101522_bib42","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1001\/archinternmed.2010.302","article-title":"Type 1 Gaucher disease: significant disease manifestations in \"asymptomatic\" homozygotes","volume":"170","author":"Balwani","year":"2010","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.beha.2023.101522_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.beha.2023.101522_bib44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/bcmd.1995.0012","article-title":"The clinical course of treated and untreated Gaucher disease. A study of 45 patients","volume":"21","author":"Beutler","year":"1995","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"10.1016\/j.beha.2023.101522_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","article-title":"Individualization of long-term enzyme replacement therapy for Gaucher disease","volume":"7","author":"Andersson","year":"2005","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101522_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/bmmb.1994.1026","article-title":"Enzyme replacement therapy for Gaucher disease: critical investigations beyond demonstration of clinical efficacy","volume":"52","author":"Brady","year":"1994","journal-title":"Biochem Med Metab Biol"},{"issue":"23","key":"10.1016\/j.beha.2023.101522_bib47","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJM199212033272304","article-title":"A less costly regimen of alglucerase to treat Gaucher's disease","volume":"327","author":"Figueroa","year":"1992","journal-title":"N Engl J Med"},{"issue":"8963","key":"10.1016\/j.beha.2023.101522_bib49","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(95)91037-9","article-title":"Individualised, low dose alglucerase therapy for type 1 Gaucher's disease","volume":"345","author":"Hollak","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beha.2023.101522_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1","volume":"11","author":"Grabowski","year":"2009","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.beha.2023.101522_bib51","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.beha.2023.101522_bib52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2021.02.005","article-title":"Gaucher disease in the COVID-19 pandemic environment: the good, the bad and the unknown","volume":"132","author":"Ginns","year":"2021","journal-title":"Mol Genet Metabol"},{"issue":"1\u20132","key":"10.1016\/j.beha.2023.101522_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol Genet Metabol"},{"issue":"2","key":"10.1016\/j.beha.2023.101522_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2020.12.291","article-title":"Gaucher disease: basic and translational science needs for more complete therapy and management","volume":"132","author":"Grabowski","year":"2021","journal-title":"Mol Genet Metabol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169262300083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169262300083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:08:55Z","timestamp":1761498535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169262300083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S152169262300083X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101522","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The international cooperative Gaucher group (ICCG) Gaucher registry","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101522"}}